[
    [
        {
            "time": "",
            "original_text": "创新药行业周报：贝达药业ALK抑制剂恩沙替尼获批",
            "features": {
                "keywords": [
                    "创新药",
                    "贝达药业",
                    "ALK抑制剂",
                    "恩沙替尼",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "创新药行业周报：贝达药业ALK抑制剂恩沙替尼获批",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：医保谈判进入关键阶段 创新药可及性进一步提升",
            "features": {
                "keywords": [
                    "医药生物",
                    "医保谈判",
                    "关键阶段",
                    "创新药",
                    "可及性",
                    "提升"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报：医保谈判进入关键阶段 创新药可及性进一步提升",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]